Effects of Gum Resin of Boswellia serrata in Patients with Chronic Colitis

Abstract

Patients studied here suffered from chronic colitis characterized by vague lower abdominal pain, bleeding per rectum with diarrhoea and palpable tender descending and sigmoid colon. The inflammatory process in colitis is associated with increased formation of leukotrienes causing chemotaxis, chemokinesis, synthesis of superoxide radicals and release of lysosomal enzymes by phagocytes. The key enzyme for leukotriene biosynthesis is 5-lipoxygenase. Boswellic acids were found to be non-redox, non-competitive specific inhibitors of the enzyme 5-lipoxygenase. We studied the gum resin of Boswellia serrata for the treatment of this disease. Thirty patients, 17 males and 13 females in the age range of 18 to 48 years with chronic colitis were included in this study. Twenty patients were given a preparation of the gum resin of Boswellia serrata (900 mg daily divided in three doses for 6 weeks) and ten patients were given sulfasalazine (3 gm daily divided in three doses for 6 weeks) and served as controls. Out of 20 patients treated with Boswellia gum resin 18 patients showed an improvement in one or more of the parameters: including stool properties, histopathology as well as scanning electron microscopy, besides haemoglobin, serum iron, calcium, phosphorus, proteins, total leukocytes and eosinophils. In the control group 6 out of 10 patients showed similar results with the same parameters. Out of 20 patients treated with Boswellia gum resin 14 went into remission while in case of sulfasalazine remission rate was 4 out of 10. In conclusion, this study shows that a gum resin preparation from Boswellia serrata could be effective in the treatment of chronic colitis with minimal side effects.

Boswellia serrata Roxb. - Burseraceae - Salai guggal - boswellic acids - leukotrienes - chronic colitis - histopathology - clinical study

References

• 1 Sharon P, Stenson W. Enhanced synthesis of LTB4 by colonic mucosa in inflammatory bowel disease.  Gastroenterology. 1984;  86 453-60
• 2 Lewis R A, Austen K F. The biologically active leukotrienes. Biosynthesis, function and pharmacology.  J. Clin. Invest.. 1984;  73 889-97
• 3 Gupta I, Parihar A, Singh G B, Lüdtke R, Safayhi H, Ammon H PT. Effects of boswellia gum resin in patients with ulcerative colitis.  Eur. J. Med. Res.. 1997;  2 37-43
• 4 Gupta I, Gupta V, Parihar A, Gupta S, Lüdtke R, Safayhi H, Ammon H PT. Effects of Boswellia serrata gum resin in patients with bronchial asthma: Results of a double-blind, placebo controlled 6 week clinical study.  Eur. J. Med. Research. 1998;  3 1-5
• 5 Safayhi H, Mack T, Sabieraj J, Anazodo M I, Subramanian L R, Ammon H PT. Boswellic acids: novel, specific, non-redox inhibitors of 5-lipoxygenase.  J. Pharm. Exp. Ther.. 1992;  261 1143-6
• 6 Safayhi H, Sailer E R, Ammon H PT. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-β-boswellic acid.  Mol. Pharmacol.. 1995;  47 1212-6
• 7 Fiske C H, Subbarow Y. Estimation of serum phosphorus.  J. Biol. Chem.. 1925;  66 375-8
• 8 Ammon H PT, Mack T, Singh G B, Safayhi H. Inhibition of leukotriene B₄ formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of Boswellia serrata .  Planta Medica. 1991;  57 203-7
• 9 Bockns N L, Roth J LA, Buckman E. Life history of non-specific colitis. Relations of prognosis of anatomical and clinical varieties.  Gastroenterologia. 1956;  86 549-52
• 10 Banks B M, Koreutz B T, Zetzel L. The course of non-specific colitis. A review of 20 years experience. Late results.  Gastroenterology. 1957;  32 983-7